ArticleSurgical neurology international2026
Association between serum glial fibrillary acidic protein levels and neurological deficit severity in acute ischemic stroke: A cross-sectional study.
Article in Surgical neurology international, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Glial fibrillary acidic protein (GFAP) is an astrocytic biomarker released following blood-brain barrier disruption in acute ischemic stroke. This study aimed to evaluate the association between serum GFAP levels and the severity of neurological deficits and to assess the diagnostic performance of GFAP in identifying severe neurological deficits. Methods: A cross-sectional analytic study was conducted at Prof. Dr. I.G.N.G. Ngoerah General Hospital, Denpasar, Bali, from April to May 2026. Eighty-five patients with neuroimaging-confirmed acute ischemic stroke were enrolled. Serum GFAP levels were measured using enzyme-linked immunosorbent assay approximately 72 h after symptom onset. Neurological severity was assessed using the National Institutes of Health Stroke Scale (NIHSS) by a blinded board-certified neurologist. Bivariate analysis, receiver operating characteristic (ROC) analysis, and multivariate logistic regression were performed. Results: The mean age was 54.14 ± 7.77 years, and 61.2% were male. Median NIHSS score was 8 (range: 3-30), and median serum GFAP level was 2.06 ng/mL (range: 0.17-19.64). Serum GFAP levels showed a strong positive correlation with NIHSS scores (r = 0.786, Conclusion: Serum GFAP levels were strongly associated with neurological severity and may serve as a potential biomarker for early stroke severity stratification.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.